Skip to main content

Social Disadvantage Tied to Worse Lung Cancer Outcomes

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

THURSDAY, Sept. 28, 2023 -- Social disadvantage is associated with a lower likelihood of achieving textbook oncological outcome and worse survival in patients with non-small cell lung cancer (NSCLC), according to a study published online Sept. 19 in JTCVS Open.

Ahmed Alnajar, M.D., M.S.P.H., from the University of Miami, and colleagues examined whether social determinants of health can affect both achievement of textbook oncological outcome and overall survival (OS) in patients with surgically resected NSCLC with pathological nodal disease. The analysis included 11,274 patients with NSCLC receiving lobectomy resection, of which 48 percent had textbook oncological outcome.

The researchers found that 15 percent of patients were considered disadvantaged (two or more social determinants of health not met), which was associated with a lower likelihood of achieving textbook oncological outcome (adjusted odds ratio, 0.85) compared with non-socially disadvantaged patients. Further, patients achieving textbook oncological outcome had lower overall mortality (adjusted hazard ratio, 0.78) than patients not achieving textbook oncological outcome. Social disadvantage remained an independently significant risk factor with OS versus not being socially disadvantaged (adjusted hazard ratio, 1.24). The impact of social disadvantage on OS was significant, regardless of textbook oncological outcome status.

"Addressing social determinants of health is important to optimize care and long-term survival of this patient population," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2023

Read this next

AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours

WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...

Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million

TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...

Patient–Primary Care Provider Language Concordance Tied to Better Outcomes

TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.